Courtesy Vedere Bio News Today : Breaking News, Live Updates & Top Stories | Vimarsana

May 18, 2021 7:00am
Vedere s first indication will be retinitis pigmentosa, a group of rare genetic disorders that damages the light-sensing cells lining the back of the eye, said CEO Cyrus Mozayeni, M.D. (Pixabay)
Cyrus Mozayeni, M.D.
(Courtesy Vedere Bio II)
Cyrus Mozayeni’s first go at vision-restoring gene therapies got snapped up as it was just getting started. Lots of suitors came knocking even when the company, Vedere Bio, was working under the radar, and Novartis eventually ponied up $150 million upfront to buy it, with a promise of $130 million more. 
Now, Mozayeni and his team are reeling in $77 million to bankroll their second chapter: Vedere Bio II. It’s technically a new entity, but it’s working on gene therapies for vision loss with the same founders, management team and employees as its predecessor. Vedere’s focus is vision loss caused by the death of photoreceptors or light-sensing cells in the retina rather than blindness stem ....

United States , Cyrus Mozayeni , University Of California , Atlas Venture , Mission Biocapital , University Of Pennsylvania , Rd Fund , Courtesy Vedere Bio , Vedere Bio , Octagon Capital , Samsara Biocapital , Casdin Capital , Editas Medicine , ஒன்றுபட்டது மாநிலங்களில் , பல்கலைக்கழகம் ஆஃப் கலிஃபோர்னியா , அட்லஸ் துணிகர , பல்கலைக்கழகம் ஆஃப் பென்சில்வேனியா , ர்ட் நிதி , எண்கோணம் மூலதனம் ,